Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TGFβ1-IN-2, a derivative of diarylacylhydrazones, effectively inhibits fibroblast activation and proliferation and holds potential for idiopathic pulmonary fibrosis (IPF) research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 397.00 | |
5 mg | In stock | $ 970.00 | |
10 mg | In stock | $ 1,180.00 | |
25 mg | In stock | $ 1,580.00 | |
50 mg | In stock | $ 1,980.00 | |
100 mg | In stock | $ 2,500.00 |
Description | TGFβ1-IN-2, a derivative of diarylacylhydrazones, effectively inhibits fibroblast activation and proliferation and holds potential for idiopathic pulmonary fibrosis (IPF) research [1]. |
In vitro | TGFβ1-IN-2 (compound 52) exhibits inhibition of NIH-3T3 cells with an IC50 of 1.36 μM [1]. Additionally, at a concentration of 6 μM over 24 hours, it suppresses TGF-β1-induced overactivity in both NIH-3T3 and A549 cells and inhibits migration and epithelial-mesenchymal transition (EMT) in A549 cells [1]. TGFβ1-IN-2 (compound 52) also binds to STAT3, interacting with Ile659, while its piperidine hydrophilic group forms intermolecular forces with Ser636, Arg609, and Pro639 [1]. |
In vivo | TGFβ1-IN-2 (compound 52) administered orally at a dosage of 30-60 mg/kg once daily for 22 days has been shown to enhance pulmonary function and decelerate the progression of Idiopathic Pulmonary Fibrosis (IPF) in mice. Additionally, this compound can potentially reverse established pulmonary fibrosis in a treatment model [1]. In rats, the pharmacokinetic profile of TGFβ1-IN-2 includes a maximum plasma concentration (C max) of 470.58±60.67 ng/mL following intravenous administration at 2 mg/kg and 351.01±85.44 ng/mL post oral administration at 20 mg/kg. The time to reach C max (T max) was 0.08 hours for intravenous and 2.17 hours for oral administration. The area under the curve (AUC 0-∞) was 370.81±76.46 h·ng/mL intravenously and 1503.71±319.62 h·ng/mL orally. The clearance rate (CL) was 5565.86±1257.13 mL/h/kg intravenously. The half-life (T 1/2) of TGFβ1-IN-2 was 0.93±0.43 hours intravenously and 1.23±0.15 hours orally, with an oral bioavailability (F) of 42.08±8.93% [1]. |
Molecular Weight | 458.57 |
Formula | C23H30N4O4S |
CAS No. | 2700263-58-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/ml
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TGFβ1-IN-2 2700263-58-5 Others inhibitor inhibit